One skirt size increase every 10 years elevates breast cancer risk
the ONA take:
According to a new study published in the journal BMJ Open, women whose skirt size increases one size every 10 years between their mid-20s and mid-60s have a 33% increased risk for developing breast cancer after menopause.
Researchers at University College London in London, United Kingdom, surveyed 92,834 women aged 50-69 years who were involved with the UK Collaborative Trial of Ovarian Cancer Screening about their present and previous skirt sizes. No participants had been diagnosed with breast cancer. On average, women had a skirt size of 8 at age 25 and a skirt size of 10 at age 64.
The researchers followed up with the women for 3 years and during that period, 1,090 women were diagnosed with breast cancer. The researchers estimated that the 5-year absolute risk of breast cancer in postmenopausal women increases with every one skirt size increase every 10 years.
In addition to the 33% increased risk for postmenopausal women whose skirt size increases one unit every decade, women whose skirt size increases two units every 10 years had a 77% increased risk for developing breast cancer post-menopause. They also found that body mass index did not help improve the prediction risk.
Women whose skirt size increases one size have increased risk for developing breast cancer.
Women who go up one skirt size every 10 years between their mid-20s and mid-60s are at a 33% greater risk of developing breast cancer after the menopause, new research has found.
Weight gain measured through an increase in body mass index (BMI) was known to be a risk factor, particularly around the midriff, but a study of 90,000 women is the first to make a connection between breast cancer and skirt size.
The results show that an expanding waistline could be more harmful. Those who went up by two sizes every decade in the same period saw an increased risk of 77%, according to the University College London study.The research could provide a valuable insight into breast cancer prevention.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|